InspireMD details COO dismissal and severance terms

InspireMD, Inc. reported that it has provided a notice of dismissal to Chief Operating Officer Andrea Tommasoli, who is employed by subsidiary InspireMD Ltd. under a French-law Employment Agreement dated November 2, 2020.

Rhea-AI Filing Summary

InspireMD, Inc. reported that it has provided a notice of dismissal to Chief Operating Officer Andrea Tommasoli, who is employed by subsidiary InspireMD Ltd. under a French-law Employment Agreement dated November 2, 2020.

The dismissal is subject to a six-month notice period and compliance with French labor laws. Tommasoli is released from his duties effective April 1, 2026, but will continue to receive base salary through the end of the notice period and health and provident benefits under French law for up to 12 months.

He will also receive severance pay of approximately €61,000 gross plus accrued unused paid leave. Subject to applicable French law, his last day of employment is expected to be September 1, 2026.

Insights

Corporate governance analyst

InspireMD discloses structured COO departure under French labor rules.

The company outlines the termination of its Chief Operating Officer, Andrea Tommasoli, with clear timing and compensation governed by a French Employment Agreement. The six-month notice period and specified benefits suggest an orderly transition rather than an abrupt change.

Financially, the package includes continued base salary during the notice period, health and provident benefits for up to 12 months, and approximately €61,000 gross severance plus unused paid leave. These obligations are defined and finite, limiting uncertainty around near-term personnel costs.

The expected last employment date of September 1, 2026 provides a clear horizon for leadership transition. Future disclosures in company filings may clarify how operational responsibilities are reassigned and whether a new COO or alternative management structure is implemented.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What executive change did InspireMD (NSPR) disclose in this 8-K?

InspireMD disclosed that Chief Operating Officer Andrea Tommasoli received a notice of dismissal. He is employed by InspireMD Ltd. under a French-law contract, and his departure follows a structured notice and benefits period rather than an immediate termination from the company.

When will InspireMD COO Andrea Tommasoli stop working and stop being employed?

Andrea Tommasoli is released from his duties effective April 1, 2026, but remains employed during a six-month notice period. Subject to French law, his last day of employment with InspireMD is expected to be September 1, 2026, after the notice and benefit arrangements conclude.

What severance will InspireMD (NSPR) pay to departing COO Andrea Tommasoli?

InspireMD expects to pay Andrea Tommasoli severance of approximately €61,000 gross and total cost. He is also entitled to the balance of any accrued and untaken paid leave, in addition to salary during the notice period and specified health and provident benefits under French law.

What ongoing salary and benefits will InspireMD’s COO receive after dismissal notice?

After the dismissal notice, Andrea Tommasoli will continue to receive his base salary through the end of the six-month notice period. He will also continue to receive health and provident benefits under applicable French law for a maximum of 12 months, alongside his other termination entitlements.

Which employment law governs InspireMD COO Andrea Tommasoli’s termination terms?

Andrea Tommasoli’s termination is governed by French law through his Employment Contract dated November 2, 2020. The dismissal is subject to a six-month notice period and full compliance with French labor rules, shaping both the timing of his departure and the compensation and benefits he will receive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 05:15 PM Learn about SEC filing dates

false 0001433607 0001433607 2026-02-27 2026-02-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 27, 2026

InspireMD, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-35731		26-2123838
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

6303 Waterford District Drive, Suite 215 Miami, Florida 33126		6744832
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (888) 776-6804

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		NSPR		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 27, 2026, InspireMD, Inc. (the “Company”) provided a notice of dismissal to Andrea Tommasoli, the Company’s Chief Operating Officer.

Mr. Tommasoli is employed by InspireMD Ltd., a wholly owned subsidiary of the Company, pursuant to an Employment Contract, dated November 2, 2020, governed by French law (the “Employment Agreement”). The termination of Mr. Tommasoli’s employment is subject to a six-month notice period for dismissal under the Employment Agreement, as well as compliance with applicable French labor laws. Mr. Tommasoli has been released from his duties effective April 1, 2026, but will continue to receive his base salary through the end of the notice period and will continue to receive health and provident benefits under applicable French Law for a maximum of 12 months. Mr. Tommasoli will also be entitled to severance pay in the amount of approximately €61,000 gross and total cost plus the balance of any accrued and untaken paid leave.

Subject to compliance with applicable French law, Mr. Tommasoli’s last day of employment with the Company is expected to be September 1, 2026.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		INSPIREMD, INC.
Date:	March 4, 2026	By:	/s/ Marvin Slosman
		Name: Title:	Marvin Slosman Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB